Results 111 to 120 of about 581 (153)
Quality of life in Australian patients with central disorders of hypersomnolence. [PDF]
Sleep AdvKinder S, Winter S, Duce B, Ellender CM.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
False positive urine amphetamine immunoassay due to solriamfetol
Sleep Medicine, 2023Solriamfetol is a schedule IV-controlled substance used to treat excessive daytime sleepiness resulting from narcolepsy or obstructive sleep apnea. We present a patient prescribed solriamfetol who tested positive for amphetamines on a routine urinary toxicology screen despite patient denial of illicit drug use, raising the possibility of a false ...
Dennis Auckley +2 more
exaly +3 more sources
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Expert Review of Clinical Pharmacology, 2019Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.
Junyi, Yang, Junfa, Gao
exaly +3 more sources
Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea
Expert Review of Respiratory Medicine, 2018Introduction: Obstructive sleep apnea (OSA) is highly prevalent and constitutes a major health hazard. Current pharmacotherapy is ineffective in correcting sleep-disordered breathing and is used adjunctively to address residual sleepiness. A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class ...
exaly +3 more sources
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea
Annals of Pharmacotherapy, 2020Objective: The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. Data Sources: A MEDLINE/PubMed ...
Jason Powell, Christopher Piszczatoski
exaly +3 more sources
Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy [PDF]
Sleep Medicine, 2022 International audienceObjectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d.Methods: In two 12-week, randomized,
Susan Redline, Shay Bujanover
exaly +2 more sources
Sleep Medicine, 2020 Objective: Solriamfetol (formerly JZP-110), a dopamine/norepinephrine reuptake inhibitor, is approved in the US to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy (75–150 mg/d) or obstructive sleep apnea (37.5 ...
Giuseppe Plazzi +2 more
exaly +3 more sources
Solriamfetol for the Management of Excessive Daytime Sleepiness
Journal of Pharmacy Practice, 2021Objective: To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). Methods: PubMed (1966 to January 2021) was ...
Megan C Cuomo +2 more
openaire +2 more sources
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial [PDF]
American Journal of Respiratory and Critical Care Medicine, 2019 Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence.
Ingo Fietze +2 more
exaly +2 more sources